h.c. wainwright news - Search News

Syros cut to neutral by H.C. Wainwright on failed drug study

H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a Phase 3 study of the company’s drug tamibarotene had failed to meet its primary endpoint.

YAHOO!Finance · 22h

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced that the Phase 3 SELECTMDS-1 trial, which evaluated tamibarotene combined with azacitidine for newly diagnosed,

MarketWatch · 1d

Syros Pharmaceuticals Shares Plummet Premarket After Study Failure

Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer. Syros late Tuesday said the Phase 3 study evaluating tamibarotene in combination with azacitidine in newly diagnosed patients with higher-risk myelodysplastic syndrome didn't meet its primary endpoint of complete response rate,

electroCore price target raised to $22 from $15 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on electroCore (ECOR) to $22 from $15 and keeps a Buy rating on the shares after the firm ...

3don MSN

Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop

Ardelyx (NASDAQ:ARDX) shares were down over 5% after H.C. Wainwright downgraded the rating for the biopharmaceutical firm, ...

Yahoo Finance21h

Opus Genetics reinstated with a Buy at H.C. Wainwright

H.C. Wainwright reinstated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target The firm believes ...

Tarsus Pharmaceuticals price target raised to $73 from $61 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $73 from $61 and keeps a Buy rating on the shares. The ...

MARA Holdings Faces Mixed Analyst Sentiment: Revenue Miss And Conservative Forecasts Amid Bitcoin Rally

MARA shares down as Q3 earnings miss estimates with lower revenue and adjusted loss, analysts maintain mixed views and price ...

bovnews8d

H.C. Wainwright Just Initiated Humacyte Inc (HUMA) Stock—What Does This Mean for Investors?

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 21.85% ...

Nasdaq22d

Ocuphire Pharma rating placed under review at H.C. Wainwright

H.C. Wainwright placed the firm’s Buy rating on Ocuphire Pharma (OCUP) under review saying the acquisition of Opus Genetics starts a new chapter. The views and opinions expressed herein are the ...

Bitcoin Miners Hive Digital, Hut 8, Bitfarms To Report Earnings As Future Of Crypto 'Has Never Been Brighter'

Bitcoin (CRYPTO: BTC) has soared to all-time highs following Donald Trump's election win, also lifting Bitcoin mining stocks on a wave of positive sentiment.

H.C. Wainwright Reaffirms Their Hold Rating on Bolt Biotherapeutics (BOLT)

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report).

Nasdaq8d

BitFuFu initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of BitFuFu (FUFU) with a Buy rating and $7 price target BitFuFu is a cloud mining service provider, meaning the company hosts bitcoin mining machines in its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results